tbuckley/cabot-search huggingface dataset:
Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population
Authors: Joon-Tae Kim, Gregg C. Fonarow, Eric E. Smith, Mathew J. Reeves, Digvijaya D. Navalkele, James C. Grotta, Maria V. Grau-Sepulveda, Adrian F. Hernandez, Eric D. Peterson, Lee H. Schwamm, Jeffrey L. Saver
Journal: Circulation (2016)

Earlier tissue plasminogen activator treatment improves ischemic stroke outcome, but aspects of the time-benefit relationship still not well delineated are: (1) the degree of additional benefit accrued with treatment in the first 60 minutes after onset, and (2) the shape of the time-benefit curve through 4.5 hours.We analyzed patients who had acute ischemic stroke treated with intravenous tissue plasminogen activator within 4.5 hours of onset from the Get With The Guidelines-Stroke US national program. Onset-to-treatment time was analyzed as a continuous, potentially nonlinear variable and as a categorical variable comparing patients treated within 60 minutes of onset with later epochs.Among 65 384 tissue plasminogen activator-treated patients, the median onset-to-treatment time was 141 minutes (interquartile range, 110-173) and 878 patients (1.3%) were treated within the first 60 minutes. Treatment within 60 minutes, compared with treatment within 61 to 270 minutes, was associated with increased odds of discharge to home (adjusted odds ratio, 1.25; 95% confidence interval, 1.07-1.45), independent ambulation at discharge (adjusted odds ratio, 1.22; 95% confidence interval, 1.03-1.45), and freedom from disability (modified Rankin Scale 0-1) at discharge (adjusted odds ratio, 1.72; 95% confidence interval, 1.21-2.46), without increased hemorrhagic complications or in-hospital mortality. The pace of decline in benefit of tissue plasminogen activator from onset-to-treatment times of 20 through 270 minutes was mildly nonlinear for discharge to home, with more rapid benefit loss in the first 170 minutes than later, and linear for independent ambulation and in-hospital mortality.Thrombolysis started within the first 60 minutes after onset is associated with best outcomes for patients with acute ischemic stroke, and benefit declined more rapidly early after onset for the ability to be discharged home. These findings support intensive efforts to organize stroke systems of care to improve the timeliness of thrombolytic therapy in acute ischemic stroke.
Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo
Authors: Felipe Samaniego, Jillian F Wise, Luis Fayad, Michelle Fanale, Fredrick Hagemeister, Vijairam Selvaraj, David M. Goldenberg, Larry W. Kwak, Zuzana Berkova
Journal: Blood (2011)
Polyreactive Monoclonal Antibodies Synthesized by Some B-CLL Cells Recognize Specific Antigens on Viable and Apoptotic T Cells.
Authors: Rosa Catera, Katerina Hatzi, Charles C. Chu, Maxime Herve’, Eric Meffre, Manlio Ferrarini, David Graham Oscier, Zadie Davis, Steven L. Allen, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2006)
Identification of Subtype-Specific Genomic Alterations of Acute and Lymphoma Types of Adult T-Cell Leukemia/Lymphoma.
Authors: Aya Oshiro, Hiroyuki Tagawa, Kouichi Oshima, Kennosuke Karube, Naokuni Uike, Yukie Tashiro, Atae Utsunomiya, Masato Masuda, Yasuo Morishima, Shigeo Nakamura, Masao Seto
Journal: Blood (2005)
The claudin expression signature of BRCA1-deficient breast cancer.
Authors: Marise R. Heerma van Voss, Petra van der Groep, Yvonne H. C. Smolders, Joost Bart, Elsken Van Der Wall, Paul J. van Diest
Journal: Journal of Clinical Oncology (2013)

e22174 Background: Unraveling the biology of BRCA1 related breast cancers may help to improve early detection methods in mutation carriers and patient tailored therapy. Claudins constitute a family of integral membrane proteins, forming the backbone of tight junctions. Altered claudin expression has been linked to oncogenesis in several ways. Decreased cellular polarity increases nutrient and growth factor supply to the rapid expanding tumor cells and decreased intercellular attachments might increase metastatic potential. The discovery of a claudin-low intrinsic subtype of breast cancer has further increased the interest in claudin expression. This study searched for distinct claudin expression profiles that characterize BRCA1 related breast cancers. Methods: 40 BRCA1 related breast cancers and 40 age-matched sporadic breast cancers were immunohistochemically stained for claudin 3, claudin 4, claudin 6 and claudin 7. Cytoplasmic and membranous expression were scored. In addition, a score was given for the overall expression (cytoplasmic and membranous combined) in comparison to the surrounding normal breast tissue. Results: Distinct claudin expression profiles were observed in BRCA1 deficient breast cancers. The hereditary cases had significantly more overexpression of claudin 3, when compared to the tumor surrounding tissue (45.7% vs 17.9%, p=0.03). Membranous claudin 6 expression was seen in 28% in BRCA1 related, compared to only 2.9% in sporadic cases (p=0.007; OR 13.2 95% CI 1.50-116). Claudin 6 was also more often overexpressed, when compared to the normal surrounding tissue in BRCA1 cases (62.5% vs. 19.4%). For claudin 7 an interesting pattern was observed. Membranous expression was observed more often in sporadic (80.0%) than hereditary (42.0%) carcinomas (p=0.001; OR 0.19 95% CI 0.07-0.50), whereas cytoplasmic expression was more abundant in BRCA1 related tumors (85.0% vs. 66.7%; p=0.06; OR 2.83 95% CI 0.95-8.46). Conclusions: Distinct claudin expression profiles characterize breast cancer in BRCA1 mutation carriers. Therefore, claudins may serve as biomarkers for diagnosis of BRCA1 related breast cancer. The mechanism of cytoplasmic relocalization of claudin 7 in BRCA1 deficient tumors deserves to be further studied.
IL-2 Stimulated Treg Inhibit in Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo,
Authors: Sarah Cooley, Veronika Bachanova, Melissa Geller, Michael R Verneris, Bin Zhang, Valarie McCullar, David McKenna, Dixie Lewis, Angela Panoskaltsis-Mortari, Daniel J. Weisdorf, Philip McGlave, Keli Hippen, Bruce R. Blazar, Jeffrey S. Miller
Journal: Blood (2011)
Role of Magnetic Ressonance Imaging – T2* in Hereditary Hemochromatosis.
Authors: Reijane Alves de Assis, Fernando Uliana Kay, Paulo Vidal Campregher, Gilberto Szarf, Fabiana Mendes Conti, Michelli da Silva Diniz, Roberta Sitnik, Morgani Rodrigues, Ricardo Helman, Marcelo Funari, Nelson Hamerschlak
Journal: Blood (2012)
Study on Effect of Low Frequency and Low Intensity Ultrasound on Leukemic Cell Lines K562 and Human Hematopoietic Cells.
Authors: Bao-An Chen, Yan Ma, Chong Gao, Jia-Hua Ding, Yun-Yu Sun, Jun Wang, Jian Cheng, Gang Zhao, Fei Fei, Ning-Na Chen
Journal: Blood (2005)
Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS).
Authors: Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz, Ekatherine Asatiani, Tania J. Curcio, Michelle K. Burton, Marjorie Fricano, Amanda R. Begley, Christine Swenson, Lawrence Mayer, Andrew S. Janoff, Arthur C. Louie
Journal: Blood (2007)
Gadolinium Containing Contrast Agent Promotes Multiple Myeloma Cell Growth: Implication for Clinical Use of MRI in Myeloma.
Authors: Mariateresa Fulciniti, Swaminathan Sundararaman, Puru Nanjappa, Samir B Amin, Prajwal Chevireddy, Neriman Gokden, Kim Hiatt, Whitney High, Masood A Shammas, Rao Prabhala, Teru Hideshima, Pierfrancesco Tassone, Kenneth C. Anderson, Sudhir V. Shah, Nikhil C. Munshi
Journal: Blood (2009)
Role of Jak3 in Chronic Myeloid Leukemia: Evidence To Identify Jak3 as a Potential Therapeutic Target.
Authors: Quan Lin, M. Ludmila Prudkin, Hagop M. Kantarjian, Jorge E. Cortes, Esther Lau, Ioannis Grammatikakis, Vilmos A. Thomazy, Raymond Lai, Hesham M. Amin
Journal: Blood (2005)
The New Prognostic Model Using Whole Blood Epstein-Barr Virus-DNA Positivity and Low Absolute Lymphocyte Count in Patients with Primary Central Nerve System Lymphoma
Authors: Ji Eun Jang, Soo Jeong Kim, June-Won Cheong, Yun Deok Kim, Yu Ri Kim, Yoo Hong Min, Jin Seok Kim
Journal: Blood (2014)
Changes of the Expressions of the Genes Involved in Iron Metabolism by the Iron Chelation Therapy in the Iron Overloaded Mouse Model.
Authors: Katsuya Ikuta, Yoshihiro Torimoto, Takaaki Hosoki, Junko Jimbo, Motohiro Shindo, Kazuya Sato, Takaaki Ohtake, Katsunori Sasaki, Yutaka Kohgo
Journal: Blood (2008)
Successful Treatment of Refractory CMV Chorioretinitis and Meningoencephalitis with Adoptive Transfer of Third Party CMVpp65 Specific T-Cell Lines
Authors: Susan Prockop, Aisha Hasan, Ekaterina Doubrovina, H.R. Castro-Malaspina, Juliet N. Barker, Parastoo B Dahi, Farid Boulad, Nancy A. Kernan, Guenther Koehne, Craig S. Sauter, Szilard Kiss, Mrinali Patel, Stephanie Suser, Richard J O'Reilly
Journal: Blood (2015)
NO EFFECT OF PRE-EXERCISE SUCRALOSE INGESTION ON GASTRIC EMPTYING RATE OF A CARBOHYDRATE-ELECTROLYTE SOLUTION
Authors: GH Evans, A Moran, C Phenton, T Pocock, E Sheader, AMW Yau
Journal: British Journal of Sports Medicine (2016)

Ingestion of carbohydrate during exercise is common in order to provide an exogenous substrate for oxidation and to improve performance. The rate at which a solution is emptied from the stomach is an important step in this process. Acute changes in blood glucose concentration significantly influence gastric emptying rate (GER). Animal studies have suggested that exposing the intestine to glucose and artificial sweeteners leads to an increase in mRNA transcription and the number of SGLT-1 transporters within the intestine. This may influence the rate of glucose absorption and GER. The aim of this study was to investigate the effects of pre-exercise sucralose ingestion on GER during exercise. Nine healthy males volunteered to participate in this study, which involved completion of two experimental trials undertaken in a fasted state. Over a two hour period, participants ingested 400 mL of water (C) or 400 mL of water containing 159 mg sucralose (S) in equal aliquots every 15 minutes. Following this, 600 mL of a commercially available carbohydrate-electrolyte solution containing 100 mg 13 C sodium acetate was ingested prior to undertaking 90 minutes of cycle exercise at 70% of heart rate reserve. Breath samples were collected pre- ingestion and at 15 minute intervals throughout exercise for measurement of GER. No differences (P&gt;0.05) were observed between trials in heart rate or rating of perceived exertion during exercise. Half emptying time of the solution was 47±16 (C) and 44±15 (S) minutes (P=0.555) while time of maximum rate of gastric emptying was 39±10 (C) and 34±10 (S) minutes (P=0.160). No difference (P&gt;0.05) between the trials was observed in delta over baseline breath values. The results of this study indicate that pre-exercise sucralose ingestion does not influence GER during exercise. This may be due to the time period of sucralose ingestion not being sufficient for adaptation to occur.
The senescence accelerated mouse prone 8 (SAMP8): A novel murine model for cardiac aging
Authors: Vengadeshprabhu Karuppagounder, Somasundaram Arumugam, Sahana Suresh Babu, Suresh S. Palaniyandi, Kenichi Watanabe, John P. Cooke, Rajarajan A. Thandavarayan
Journal: Ageing Research Reviews (2016)
Industry funded studies are less likely to link sugary drinks to obesity, review finds
Authors: Susan Mayor
Journal: BMJ (2016)

Research studies funded by companies that make sugar sweetened beverages are significantly less likely to find links between sugary drinks and obesity or diabetes related outcomes than independently funded studies, a review of the literature has found.1

Recent regulatory initiatives to limit consumption of sugary drinks, including tax measures and nutritional guidance, have hinged on whether these beverages cause obesity and diabetes. The drinks industry …
Nearly half of all trials run by major sponsors in past decade are unpublished
Authors: Gareth Iacobucci
Journal: BMJ (2016)

The drug company Sanofi has failed to publish results for almost two thirds of the clinical trials it has conducted in the past decade, a major new tracking service has disclosed.

TrialsTracker, a new automated service launched to shine a spotlight on drug companies and universities, found that nearly half of all trials run by major sponsors in the past 10 years were missing results.1

Sanofi, the multinational drug company based in France, had the highest number of missing results (285 missing results, 65.5% of those conducted). The next highest number of missing results was from Novartis Pharmaceuticals (201, 37.6%), followed by the US National Cancer Institute (194, 34.8%), Assistance Publique-Hopitaux …
An Effective Hematopoietic Stem Cell Mobilization Algorithm for Adding Plerixafor to G-CSF for Multiple Myeloma Patients Undergoing Autologous Transplantation
Authors: Justin LaPorte, Scott R. Solomon, Asad Bashey, H. Kent Holland, Lawrence E. Morris, Connie A. Sizemore, Melissa Sanacore, Ronald Mihelic, Mindy Leech, Irina Grigorieva, Xu Zhang
Journal: Blood (2011)
The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG
Authors: Marek Trneny, Robert Pytlik, David Belada, Katerina Kubackova, Milada Jankovska, Tomas Papajik, Jan Pirnos, Hana Krejcova
Journal: Blood (2008)
Discovery of Recurrent Mutations Associated with Chemo-Immunotherapy Relapse in Diffuse Large B-Cell Lymphoma
Authors: Jillian Frances Wise, Sigve Nakken, Daniel Vodak, Gunhild Trøen, Ole Christian Lingjærde, Leonardo A. Meza-Zepeda, Ola Myklebost, Klaus Beiske, June Helen Myklebust, Eivind Hovig, Erlend Smeland, Harald Holte
Journal: Blood (2015)
Nuclear Proteomics Uncovers Diurnal Regulatory Landscapes in Mouse Liver
Authors: Jingkui Wang, Daniel Mauvoisin, Eva Martin, Florian Atger, Antonio Núñez Galindo, Loïc Dayon, Federico Sizzano, Alessio Palini, Martin Kussmann, Patrice Waridel, Manfredo Quadroni, Vjekoslav Dulić, Felix Naef, Frédéric Gachon
Journal: Cell Metabolism (2016)

Diurnal oscillations of gene expression controlled by the circadian clock and its connected feeding rhythm enable organisms to coordinate their physiologies with daily environmental cycles. While available techniques yielded crucial insights into regulation at the transcriptional level, much less is known about temporally controlled functions within the nucleus and their regulation at the protein level. Here, we quantified the temporal nuclear accumulation of proteins and phosphoproteins from mouse liver by SILAC proteomics. We identified around 5,000 nuclear proteins, over 500 of which showed a diurnal accumulation. Parallel analysis of the nuclear phosphoproteome enabled the inference of the temporal activity of kinases accounting for rhythmic phosphorylation. Many identified rhythmic proteins were parts of nuclear complexes involved in transcriptional regulation, ribosome biogenesis, DNA repair, and the cell cycle and its potentially associated diurnal rhythm of hepatocyte polyploidy. Taken together, these findings provide unprecedented insights into the diurnal regulatory landscape of the mouse liver nucleus.
Effects of Maternal Age and Age-Specific Preterm Birth Rates on Overall Preterm Birth Rates — United States, 2007 and 2014
Authors: Cynthia Ferré, William Callaghan, Christine Olson, Andrea Sharma, Wanda Barfield
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Reductions in births to teens and preterm birth rates are two recent public health successes in the United States (1,2). From 2007 to 2014, the birth rate for females aged 15-19 years declined 42%, from 41.5 to 24.2 per 1,000 females. The preterm birth rate decreased 8.4%, from 10.41% to 9.54% of live births (1). Rates of preterm births vary by maternal age, being higher among the youngest and oldest mothers. It is unknown how changes in the maternal age distribution in the United States have affected preterm birth rates. CDC used birth data to assess the relative contributions of changes in the maternal age distribution and in age-specific preterm birth rates to the overall decrease in preterm birth rates. The preterm birth rate declined in all age groups. The effects of age distribution changes on the preterm birth rate decrease were different in younger and older mothers. The decrease in the proportion of births to mothers aged ≤19 and 20-24 years and reductions in age-specific preterm rates in all age groups contributed to the overall decline in the preterm birth rate. The increase in births to mothers aged ≥30 years had no effect on the overall preterm birth rate decrease. The decline in preterm births from 2007 to 2014 is related, in part, to teen pregnancy prevention and the changing maternal age distribution. Effective public health strategies for further reducing preterm birth rates need to be tailored to different age groups.
Abstract 15928: A Mobile Health Driven Walking Program Improves Quality of Life but not Fitness or Fatness in Obese Sedentary Women
Authors: Kerry J Stewart, Jonathan Katz, Meredith Dobrosielski, Pamela Ouyang
Journal: Circulation (2015)

Background: Many mHealth programs exist for increasing physical activity (PA) yet few have been tested for their effects on fitness, fatness, and health related quality of life (HRQOL). Methods: We conducted a 3-month randomized trial that examined 2 message formats that promoted the 10,000 steps/day walking program. Women (n=70), aged 48±12 years, BMI 35.0 ±3.8, with self-report of no regular (PA), were given a FitBit and smartphone, which automatically sent daily step data to us daily. Daily messages with feedback about meeting step goals and motivation to add 500 more daily steps/week were sent to the subject’s smartphone. We compared the Multimedia Messaging Service (MMS) consisting of audio, video and graphs versus the Short Message Service (SMS), or plain text messages. Message content was the same for both groups. Outcomes included the 6-minute walk test, weight, waist and hip circumferences, BMI, SF-36, and Profile of Mood States (POMS). We hypothesized that MMS subjects would be more engaged, walk more, and attain greater gains in study outcomes. Results: We delayed messaging for the first 2 weeks to establish a daily step baseline, which was 6665 ±2270. There were no group differences in daily steps at baseline or at any time point in the study. Daily steps in Month 1 was 6926±2465; Month 2, 7327± 3310; and Month 3, 6642±2914. The increases from baseline to the full Month 1 (p=0.004) and Month 1 to 2 (p=0.025) were significant but not the decrease from Month 2 to 3. The FitBit was worn 91% of study days in both groups. There were no changes or group differences in any fitness or fatness measure. Both groups similarly improved SF-36 General Health (p=0.02) and Vitality (p=0.01); and POMS Fatigue (p=0.01), Vigor (p=0.001), Tension-Anxiety (p=0.03), and Total Mood Score, (p=0.02). Conclusions: Baseline steps were about 2-3 times more than expected for sedentary women. It seems that the novelty of using a tracking device accelerated the planned progression for walking, with a much higher than expected step count initially and then a slight drop over time. An average of 10,000 steps/day was not met. There were no changes in physical measures though indicators of HRQOL improved. Contrary to our hypothesis, the different messaging formats did not affect outcomes.
The New CMS Hospital Quality Star Ratings
Authors: Karl Y. Bilimoria, Cynthia Barnard
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248).
Authors: Jolie Ringash, John N. Waldron, Lillian L. Siu, Rosemary Martino, Eric Winquist, Jim R. Wright, Abdenour Nabid, John H Hay, Alex Hammond, Khalil Sultanem, Sebastien Hotte, Carson Leong, Ali Abdel Halim El-Gayed, Farah Naz, Kevin Ramchandar, Tim E Owen, Alexander Montenegro, Brian O'Sullivan, Bingshu E. Chen, Wendy R. Parulekar
Journal: Journal of Clinical Oncology (2015)

6053 Background: Addition of concurrent anti-EGFR monoclonal antibody to radiotherapy alone did not worsen QOL (Curran 2007). We compared standard chemoradiotherapy (cRT) to bioradiotherapy (bRT). Methods: Pts with T any N+M0 or T3-4N0M0 untreated LA-SCCHN were randomized 1:1 to receive SFX (70Gy/35/7 weeks) plus CIS at 100 mg/m2intravenous (IV) for 3 doses on weeks 1, 4 and 7 versus AFX (70Gy/35/6 weeks) plus the anti-EGFR monoclonal antibody PMab at 9 mg/kg IV for 3 doses on weeks -1, 3 and 6. QOL was collected at baseline, end of RT, and 2, 4, 6, 12, 24 and 36 months post-RT using validated instruments FACT-H&N, MDADI and SWAL-QOL. All analyses were intent-to-treat. We hypothesized a 6-points more favourable change in FACT-H&N score from baseline to 1 year post-treatment in the bRT arm relative to cRT. Results: From 12/2008 to 11/2011, 320 pts were randomized, 160 to cRT and 160 to bRT, with median follow-up of 46.4 (range: 0.1-64.3) months. Median age 56, 84% male, ECOG PS 0 (71%), 1 (29%). Primary site was oropharynx in 81% (p16 +68%, - 11%, missing 21%), larynx (11%), hypopharynx (6%), oral cavity (2%). Smoking history was > 10 pack-years in 58%, < = 10 in 12%; 28% were never-smokers. All compliance exceeded 80%. Baseline scores did not differ by arm (cRT/bRT): FACT-H&N 110/110, MDADI Global 83/77, SWAL-QOL General 67/68. At 1 year, no statistically or clinically significant difference was seen between arms in FACT-H&N change from baseline: cRT 4.23, bRT 1.88, p = 0.129. Differences were only seen during the last week of radiotherapy, for (cRT: bRT): FACT-Physical Well-Being (-11.6, -10, p = 0.049), MDADI Physical subscale (-40.4, -33.9, p = 0.045), and SWAL-QOL Eating Duration (-61.2, -51.2, p = 0.02), Eating Desire (-53.3, -43.9, p = 0.031) and Mental Health (-42, -32.6, p = 0.009). No differences by arm on any scale were seen post-treatment. Conclusions: Despite transient benefits at the end of RT, the combination of PMab with AFX did not durably improve QOL as compared to SFX with CIS. Clinical trial information: NCT00820248.